The comparison that matters
| Feature | CJC-1295 with DAC | “CJC-1295 no DAC” / modified GRF 1-29 |
|---|---|---|
| Albumin-binding DAC | Present | Absent |
| Human PK evidence | Randomized healthy-adult studies | No equivalent published human PK dataset identified |
| Measured / commonly cited half-life | 5.8–8.1 days in human study | Short-acting; exact human estimate is uncertain |
| Exposure pattern | Sustained multi-day exposure | Brief exposure associated with modified GRF naming |
What the DAC attachment does
The Drug Affinity Complex is a reactive chemical group designed to bind to albumin after administration. Albumin circulates for much longer than an unprotected peptide, so attaching the analogue to albumin slows clearance. The original CJC-1295 human study reported sustained increases in growth hormone for six days or more and IGF-1 for nine to eleven days after a single injection.
Why the “no DAC” name creates confusion
Published CJC-1295 clinical data primarily concern the DAC-containing molecule. In commercial and community usage, “CJC-1295 without DAC” is often applied to modified GRF 1-29. Removing the defining albumin-binding component changes the pharmacokinetic identity, so evidence from the DAC form cannot simply be transferred to the no-DAC label.
Use the separate database entries for CJC-1295 with DAC and CJC-1295 no DAC to keep the evidence sets distinct.
What is actually known from human research?
In two randomized, placebo-controlled, double-blind studies of healthy adults, CJC-1295 with DAC had an estimated half-life of 5.8 to 8.1 days. Multiple doses produced cumulative effects, and mean IGF-1 remained above baseline for up to 28 days. A separate study found that pulsatile GH secretion persisted during continuous stimulation by the long-acting analogue.
Those findings should not be rewritten as proof for modified GRF 1-29. The chemically and pharmacokinetically distinct form needs its own evidence.
How to read any CJC-1295 claim
- Check whether the source explicitly says DAC, Drug Affinity Complex, or albumin binding.
- Confirm whether the half-life comes from a human PK study or is repeated from vendor copy.
- Do not assume evidence for one form establishes outcomes or safety for the other.
- Check regulatory status before interpreting protocol claims.
Frequently asked questions
What does DAC mean in CJC-1295?
DAC means Drug Affinity Complex. It allows CJC-1295 to bind covalently to circulating albumin, substantially extending its plasma half-life.
What is the half-life of CJC-1295 with DAC?
A randomized human study estimated the half-life of CJC-1295 with DAC at approximately 5.8 to 8.1 days.
Is CJC-1295 no DAC the same compound?
The name CJC-1295 no DAC is commonly used for modified GRF 1-29, but it lacks the albumin-binding DAC attachment and should not be treated as pharmacokinetically equivalent to studied CJC-1295 with DAC.